Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Influsplit SSW · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Influsplit SSW® | BIOLOGICAL | - |
Inclusion Criteria: * Subjects who the investigator believes that they can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return, and follow-up visits) should be enrolled in the study. * All Subjects, enrolled in this study, must not been immunized agains...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
Influsplit SSW is an investigational monoclonal antibody developed by GSK plc for influenza. It is in Phase 3 clinical development in the infectious disease therapeutic area. The asset has been studied in a single completed Phase 3 trial conducted in Germany.
Influsplit SSW is being developed for influenza. Its clinical program has focused on this infectious disease indication, with one completed Phase 3 study in Germany enrolling 120 participants aged 18 years and older, including healthy volunteers.
Influsplit SSW is developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor behind the asset's clinical development program in influenza.
Influsplit SSW is in Phase 3 development. It is an investigational monoclonal antibody and has not been approved. One Phase 3 trial has been completed, and no trials are currently active.
Influsplit SSW has been studied in one completed Phase 3 trial, NCT00306943, titled Annual Study for Fluarix Registration. The trial enrolled 120 participants in Germany, was uncontrolled, and included adults aged 18 years and older, with healthy volunteers eligible.
Yes, Influsplit SSW and Influsplit SSW® refer to the same asset. The registered trademark form Influsplit SSW® is an alternative name for the GSK monoclonal antibody in development for influenza.